|Bid||0.1700 x 1100|
|Ask||0.1715 x 3200|
|Day's Range||0.1650 - 0.1736|
|52 Week Range||0.1400 - 0.5900|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.80|
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a share purchase agreement with certain accredited institutional investors to purchase 19,440,000 shares of its common stock in a registered direct offering at a purchase price of $0.14 per share.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved the proposal to amend Titan's certificate of incorporation to increase the number of authorized shares of common stock from 125 million to 225 million (the "Amendment").
Sunil Bhonsle has been the CEO of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) since 2015, and this article will examine...